Skip to main content
Signal8

Virpax Pharmaceuticals, Inc. (VRPX)

Virpax Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical enterprise, dedicated to pioneering diverse drug-delivery systems and novel drug-releasing technologies. Its core focus lies in developing advanced, non-opioid and non-addictive solutions for pain management, alongside therapies targeting central nervous system disorders. The company's current investigational pipeline features several preclinical product candidates. These include Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) designed to address chronic osteoarthritis of the knee, and Probudur, an injectable liposomal gel formulated as a local anesthetic for managing post-operative pain. Also in development are Envelta and PES200, both nanotechnology-based intranasal spray drug candidates engineered to deliver metabolically labile peptide drugs directly to the brain. Further candidates comprise AnQlar, an antiviral barrier solution intended to prevent or lessen the severity of human viral infections such as influenza and SARS-CoV-2, and VRP324, an experimental nasal formulation aimed at enhancing the transport of cannabidiol into the brain. Virpax Pharmaceuticals, Inc. was established in 2016 and is based in Berwyn, Pennsylvania.

Sector: Biotechnology

Industry: Biotechnology

Virpax Pharmaceuticals, Inc. logo

Virpax Pharmaceuticals, Inc.

OTC:VRPXHealthcare
+25.00%$0.0020
CLOSED
Mkt Cap$2K
EV-
Float1.06M
O/S1.24M
VOL356 sh
$ Vol$1
RVOL0.33×
Inst Own-
SI1.1%
Net Cash/Sh-
Dilution
Virpax Pharmaceuticals, Inc. logoOTC:VRPXClosed$0.0020+25.00%
Short interest (FINRA)
1.1%
Oct 30 (18d)

Float 1.06M · FMP free float

11.4K
Oct 30 (18d)prev 11.4K– 0.0%
13.78
Oct 30 (18d)prev 27.43▼ 49.8%
Borrow (IBKR)

The cost to borrow VRPX shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 202611.4K sh
Oct 15, 202611.4K sh
Sep 30, 202611.4K sh
Sep 15, 202611.9K sh
Aug 31, 202611.9K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

FINRA publishes no off-exchange short volume for this symbol.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for VRPX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 11,410 VRPX shares were sold short (1.07% of a 1.06M-share float, 13.78 days to cover).